# Innovent Biologics 與輝瑞達成一項價值105億美元的突破性合作協議。

*biotech · news · 2026-05-30 · Devdiscourse*

## Key points

- Innovent Biologics 與輝瑞簽署一項105億美元的合作協議，共同開發12款癌症藥物。
- 輝瑞將預付 Innovent 6.5億美元，並可能根據里程碑支付進一步款項。
- 該協議聚焦於早期腫瘤藥物，並利用中國日益增強的生技能力。
- 此交易標誌著西方與亞洲製藥公司合作的新規模。

Innovent Biologics and Pfizer have entered a groundbreaking partnership, valued at $10.5 billion, to develop a dozen early-stage cancer drugs. This strategic move capitalizes on China's thriving biotech industry. The agreement includes an upfront payment of $650 million to Innovent and anticipates additional payments based on developmental milestones. This deal reflects a global push among pharmaceutical giants to leverage the rapidly expanding biotech sector in Asia, highlighting an increasing collaboration between Western and Asian drug developers. (With inputs from agencies.)

**Companies:** Pfizer, Innovent Biologics
**Countries:** China, United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3926961-cancer-collaboration-soars-innovent-and-pfizers-105b-biotech-boom)

---

Canonical: https://newsio.io/zh-TW/n/daa0b0f8-24fc-4793-9c55-3ec2b4503f35/innovent-biologics-105
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works